Canaccord raised the firm’s price target on Globus Medical (GMED) to $85 from $70 and keeps a Buy rating on the shares. The firm said the company continued its strength from earlier quarters into the Q3 with a significant top- and bottom-line beat driving record FCF and raising of guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $100 from $80 at Piper Sandler
- Globus Medical price target raised to $87 from $78 at BTIG
- Globus Medical price target raised to $80 from $55 at BofA
- Globus Medical price target raised to $88 from $78 at Wells Fargo
- Globus Medical Reports Robust Q3 2024 Financial Growth
Questions or Comments about the article? Write to editor@tipranks.com